The Board of Directors of Genovis AB (publ) resolves on fully underwritten rights issue and reschedules Annual General Meeting to May 5, 2015

The Board of Directors of Genovis AB (publ) has decided to reschedule the Annual
General Meeting to May 5, 2015, as well as to raise capital through a fully
underwritten rights issue, subject to approval by the AGM on May 5, 2015. The
rights issue comprises a maximum of 14,563,768 shares and the subscription price
will be SEK 1 per share. At full subscription the rights issue will raise
approximately SEK 14.5 million before issue expenses for Genovis.
Genovis is experiencing strong confidence in the company's products, with
growing demand in both Europe and the US. The purpose of the rights issue is to
be able to maintain the pace of sales and allow for a more powerful expansion in
these two markets. Subscription and underwriting commitments have been obtained,
corresponding to 100 percent of the total proceeds of the rights issue.

The Board proposes that the Annual General Meeting approve the Board’s proposal
to conduct a preferential rights issue of shares in which three (3) existing
shares entitle the holder to subscription for two (2) new shares at a
subscription price of SEK 1/ share. As a result of this resolution share capital
could increase by a maximum of SEK 3,640,942 through the issuance of up to
14,563,768 shares. In the event that all shares are not subscribed for on the
basis of subscription rights, allocation of shares shall be made within the
scope of the maximum amount of the share issue, at which the Board shall
allocate the shares firstly to those who have subscribed for shares on basis of
subscription rights, pro rata in relation to their subscription on the basis of
subscription rights, secondly to those who have declared their interest to
subscribe for shares without subscription rights, pro rata in relation to their
declared interest and last to guarantors in proportion to their guarantee
undertakings.

Following the completed rights issue, share capital will amount to a maximum of
SEK 9,102,355 and the number of shares to a maximum of 36,409,420. The company
will raise about SEK 14.5 million before issue expenses, which are expected to
be about SEK 500,000. The issue will have a dilutive effect of 40 percent on the
holdings of those who do not subscribe to the rights issue for their full stake.

Timetable for rights issue

May 11, 2015: Last trading day for the Genovis share including subscription
rights for the new issue.

May 13, 2015: Record date for participation in the new issue; shareholders
registered in Genovis’ share register on this day receive subscription rights
for participation in the new issue.

May 18 – June 1, 2015: Subscription period, subscription with preferential
rights through cash payment during the subscription period. Shareholders may
report their intention to subscribe throughout the subscription period.

Resolutions on the issuance of shares are subject to and conditional upon the
Meeting also resolving on reduction of share capital and amendment of the
Articles of Association; both of these resolutions are proposed to the same
General Meeting.

A Memorandum will be sent to the company’s shareholders that will provide the
full terms, instructions and more information on the rights issue and Genovis.
The Memorandum will be available on the company’s website www.genovis.com
beginning on May 13, 2015.

The notice is published in a separate press release and will be published in
Post- och Inrikes tidningar and on the company's website within the next few
days.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
0046 (0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00